亚星化学（600319）拟通过发行股份及支付现金的方式购买天一控股等24名股东持有的天一化学100% 股权。同时，拟向包括潍坊市城投集团在内的不超过35名符合条件的特定投资者发行股份募集配套资 金。本次交易预计构成重大资产重组，本次交易完成后，上市公司的主要产品将新增溴系列精细化工产 品，以及标的公司新材料板块、钾盐板块、膜材料板块的各项产品。本次交易有助于公司完善产品布 局，增强盈利能力。 润农节水拟向控股股东湖北乡投集团定增募资不超8451万元，发行价6.26元/股，发行数量1350万股。 湖北乡投集团以现金方式认购本次发行的全部股份。（数据宝） 11月18日共有5家公司公布非公开发行预案。 生益电子拟向不超过35名特定投资者非公开发行，拟发行数量不超过1.25亿股，预计募集资金26.00亿 元，募集资金主要用于人工智能计算HDI生产基地建设项目；智能制造高多层算力电路板项目；补充流 动资金和偿还银行贷款。 豪美新材（002988）拟向不超过35名(含)特定投资者非公开发行，拟发行数量不超过7492.55万股，预计 募集资金18.97亿元，募集资金主要用于华东汽车轻量化高性能铝型材及零部件产能扩充项目；华 ...

注：本文系新闻报道，不构成投资建议，股市有风险，投资需谨慎。 亚星化学开盘涨停，公司今日披露非公开发行预案，拟通过发行股份及支付现金的方式购买天一控股等 24名股东持有的天一化学100%股权。同时，拟向包括潍坊市城投集团在内的不超过35名符合条件的特 定投资者发行股份募集配套资金。本次交易预计构成重大资产重组。 本次交易完成后，上市公司的主要产品将新增溴系列精细化工产品，包括四溴双酚A、溴化环氧树脂、 溴化聚苯乙烯、十溴二苯乙烷、氢溴酸等，以及标的公司新材料板块、钾盐板块、膜材料板块的各项产 品。本次交易有助于公司完善产品布局，增强盈利能力。（数据宝） （原标题：亚星化学开盘涨停，公司非公开发行预案披露） ...

大家早上壕！ 先看海外要闻： 三大美股指齐创一个月新低，标普500跌0.92%，道指跌1.18%，纳指跌0.84%。 金融和能源板块跌近2%、领跌标普；芯片指数跌超1%、三连跌，英伟达回落近2%；但被伯克希尔建仓后，谷歌逆市反弹超3%。 中概指数跌超1%、五连跌，小鹏汽车财报后跌10%。 美债价格跌势消减，十年期美债收益率在连升两日后回落。 国内重大事件汇总： 1、中德高级别财金对话在京举行，达成多项成果共识，结束贸易紧张局势。 2、中国产业发展促进会氢能分会以"拒绝内卷 共建生态 迈向真实市场化"为主题举行研讨会，联合产业各方共同发布《中国电解槽行业健康发展 倡议书》。 3、商务部等7部门发布关于开展茧丝绸产业"东绸西固"工作的通知：鼓励创建区域公用品牌，引导头部企业与国际时尚品牌合作。 4、药监局发布关于深化化妆品监管改革促进产业高质量发展的意见：鼓励化妆品新品在中国首发，畅通新功效化妆品注册渠道，实行即报即 审。 5、国家发展改革委联合财政部等部门印发《关于加快建设现代化国有林场的意见》，明确持续提高国有林场生态质量功能，提升优质生态产品 供给能力，加快补齐发展短板，促进国有林场在生态保护、绿色发展、富 ...

重要新闻提示 平潭发展、海峡创新：因股票交易异常波动，今起停牌核查 嘉戎技术：筹划购买杭州蓝然全部股份，预计构成重大资产重组 亚星化学：重大资产重组预案出炉，今日复牌 3. 财政部11月17日发布的2025年1—10月财政收支情况显示，1—10月主要税收收入项目中，印花税收入 3781亿元，同比增长29.5%。其中，证券交易印花税收入1629亿元，同比增长88.1%。 今日提示 央行今日有4038亿元7天期逆回购到期 北交所新股精创电气（920035）今日申购，发行价为12.1元/股 科创板新股恒坤新材（688727）、创业板新股南网数字（301638）、北交所新股北矿检测（920160）今 日上市 财经新闻 1. 11月17日，国家药监局发布《关于深化化妆品监管改革促进产业高质量发展的意见》。《意见》明确 了改革的指导思想和主要目标，提出到2030年，化妆品监管法律制度更加完善，标准体系更加健全，技 术支撑更加有力，产业创新活力更加充沛，风险防控能力全面加强，质量安全水平显著提升；到2035 年，化妆品质量安全监管体系达到国际先进水平，产业具有更强的创新创造力和全球竞争力，基本实现 监管现代化。 2. 国家 ...

本次交易完成后，上市公司的主要产品将新增溴系列精细化工产品，包括四溴双酚A、溴化环氧树脂、 溴化聚苯乙烯、十溴二苯乙烷、氢溴酸等，以及标的公司新材料板块、钾盐板块、膜材料板块的各项产 品。 经向上海证券交易所申请，公司股票将于2025年11月18日开市起复牌。 格隆汇11月17日丨亚星化学(600319.SH)公布，公司拟通过发行股份及支付现金的方式购买山东天一控 股集团股份有限公司等24名股东持有的山东天一化学股份有限公司100%股权，并募集配套资金。 ...

本次交易完成后，上市公司的主要产品将新增溴系列精细化工产品，包括四溴双酚A、溴化环氧树脂、 溴化聚苯乙烯、十溴二苯乙烷、氢溴酸等，以及标的公司新材料板块、钾盐板块、膜材料板块的各项产 品。本次交易有助于公司完善产品布局，增强盈利能力，为公司的持续发展和行业地位的巩固奠定坚实 基础。 亚星化学（600319）(600319.SH)发布公告，公司拟通过发行股份及支付现金的方式购买天一控股等24 名股东持有的天一化学100%股权。同时，上市公司拟向包括潍坊市城投集团在内的不超过35名符合条 件的特定投资者发行股份募集配套资金。 经向上海证券交易所申请，公司股票将于2025年11月18日开市起复牌。 ...

智通财经APP讯，亚星化学(600319.SH)发布公告，公司拟通过发行股份及支付现金的方式购买天一控 股等24名股东持有的天一化学100%股权。同时，上市公司拟向包括潍坊市城投集团在内的不超过35名 符合条件的特定投资者发行股份募集配套资金。 本次交易完成后，上市公司的主要产品将新增溴系列精细化工产品，包括四溴双酚A、溴化环氧树脂、 溴化聚苯乙烯、十溴二苯乙烷、氢溴酸等，以及标的公司新材料板块、钾盐板块、膜材料板块的各项产 品。本次交易有助于公司完善产品布局，增强盈利能力，为公司的持续发展和行业地位的巩固奠定坚实 基础。 经向上海证券交易所申请，公司股票将于2025年11月18日开市起复牌。 ...

Core Viewpoint - Yaxing Chemical (600319) announced a major asset restructuring plan, intending to acquire 100% equity of Tianyi Chemical from 24 shareholders through a combination of share issuance and cash payment, with trading resuming on November 18 [1] Group 1: Transaction Details - The transaction is expected to constitute a significant asset restructuring and related party transaction, but it will not qualify as a restructuring listing [1] - Yaxing Chemical plans to raise supporting funds by issuing shares to no more than 35 qualified specific investors, including Weifang City Investment Group [1] Group 2: Business Impact - Tianyi Chemical operates in four main sectors: flame retardants, new materials, potassium salts, and membrane materials, and is a leading supplier in the brominated flame retardants market in China [1] - Post-transaction, Yaxing Chemical's product portfolio will expand to include brominated fine chemical products such as tetrabromobisphenol A, brominated epoxy resin, brominated polystyrene, decabromodiphenyl ether, and hydrobromic acid, along with products from Tianyi Chemical's new materials, potassium salts, and membrane materials sectors [1]

Core Viewpoint - The announcement of a major restructuring plan by Yaxing Chemical to acquire control of Tianyi Chemical has generated significant interest in the market, with questions about its potential to reverse Yaxing's continuous losses [1][5]. Group 1: Acquisition Details - Yaxing Chemical plans to acquire control of Tianyi Chemical through a combination of issuing shares and cash payments, which is expected to constitute a major asset restructuring and related party transaction [1][5]. - Tianyi Chemical, established in 2002, specializes in bromine series fine chemicals with an annual production capacity exceeding 60,000 tons and an annual output value of approximately 1 billion yuan [3]. - Tianyi Chemical has a dominant market position in its niche, holding over 50% market share in certain products domestically and up to 70% internationally for some water-based functional monomers [3]. Group 2: Financial Performance - Yaxing Chemical has faced declining performance, reporting a net loss of approximately 97.03 million yuan in 2024 and a negative net profit of 144 million yuan in the first three quarters of 2025 [3][7]. - The company has highlighted risks related to funding security in its annual and semi-annual reports, indicating financial constraints [3]. Group 3: Strategic Rationale - The acquisition is seen as a strategic move for Yaxing Chemical to enhance its market share and technological capabilities, potentially compensating for its weaknesses in new materials and high-end chemicals [7]. - Tianyi Chemical claims to have overcome several international monopolistic technologies, which could provide Yaxing with valuable technical advantages [5]. Group 4: Challenges and Considerations - The transaction involves complexities such as funding, equity dilution, and related party transactions, which require careful management and integration with existing operations [7][9]. - The timing of the acquisition coincides with Yaxing's major project launches, raising concerns about resource allocation and operational focus [9][11]. - Successful completion of the deal could enhance Yaxing's product lines and market share, but it also faces risks related to integration costs and short-term financial pressures [11].

Core Viewpoint - The article discusses the planned acquisition of Tianyi Chemical by Weifang Yaxing Chemical, highlighting the strategic move amidst Yaxing's declining performance and financial challenges [1][8]. Group 1: Acquisition Details - Weifang Yaxing Chemical announced plans to acquire control of Tianyi Chemical through a combination of share issuance and cash payment, along with raising supporting funds [1]. - The transaction is expected to constitute a major asset restructuring, leading to a temporary suspension of Yaxing's stock trading for up to 10 trading days [2]. - The acquisition is classified as a related party transaction due to shared controlling shareholders between the two companies [3]. Group 2: Financial Performance of Yaxing Chemical - Yaxing Chemical has experienced a decline in operational performance, with a reported revenue of 641 million yuan for the first three quarters of 2025, a year-on-year decrease of 2.53%, and a net loss of 144 million yuan [6]. - The company's cash flow from operating activities was negative 50.9 million yuan, indicating insufficient cash generation from its core business [7]. - The decline in performance is attributed to intensified competition in the CPE product market and a decrease in downstream demand, coupled with raw material prices not decreasing in tandem with finished product prices [7]. Group 3: Financial Condition and Strategic Implications - Yaxing Chemical's asset-liability ratio reached 85.15% as of September 30, 2025, significantly higher than the chemical industry average of 50%-60%, raising concerns about its financial stability [8]. - The acquisition of Tianyi Chemical is viewed as a potential strategic shift for Yaxing, aiming to enhance its profitability amid a shrinking traditional chlorine-alkali business [8][14]. - Tianyi Chemical, established in 2002, specializes in bromine series fine chemical products and had a revenue of 1.638 billion yuan and a net profit of 240 million yuan in 2021, indicating a stronger financial position compared to Yaxing [10][12]. Group 4: Challenges in the Acquisition - The acquisition is characterized as a "snake swallowing an elephant" due to the disparity in size and financial metrics between Yaxing and Tianyi [12]. - Tianyi Chemical's complex ownership structure poses significant challenges for Yaxing, with 24 shareholders, including a controlling shareholder holding 56.36% of the shares [14].